Reify Health and SubjectWell Partner to Boost Patient Recruitment
Reify Health and SubjectWell have announced an innovative partnership aimed at restructuring the workflow of research sites to manage patient referrals from sponsor-driven recruitment campaigns. With this pairing, referrals from SubjectWell’s marketplace are delivered directly into Reify Health’s StudyTeam, offering a common platform for sites and sponsors to manage pre-screening, enrollment, and reporting for clinical trials.
With this partnership, SubjectWell’s qualified referrals are delivered via Reify Health’s Recruitment Partner Interface (RPI) directly into StudyTeam. Sites are then able to update, manage, and report on the entire enrollment funnel from a single, secure platform.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
